Still, the agency warned it's not clear whether any of these will work against the deadly virus that has already killed over 4,800 people this year in West Africa.
Dr Marie-Paule Kieny from the UN health agency told reporters that millions of doses of an Ebola vaccine could be available in 2015 if early tests prove that the two leading candidates are safe and effective.
Trials of those two most advanced vaccines one developed by GlaxoSmithKline in cooperation with the US National Institute of Health, the other developed by the Canadian Public Health Agency have already begun in the US, UK and Mali.
If the early vaccine trials hint at success, larger trials testing the vaccines in West Africa could begin as soon as December, Kieny said; previously the trials weren't scheduled to start until January.
She also said five other possible Ebola vaccines should start being tested in March.
Yet in an indication of how the rising spread of Ebola is upending many attempts to halt this year's outbreak, Kieny admitted that plans were changing "week to week" as governments, health agencies and donor countries tried to speed up efforts to fight the deadly virus.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
